XLO
Income statement / Annual
Last year (2025), Xilio Therapeutics Inc's total revenue was $43.77 M,
an increase of 589.88% from the previous year.
In 2025, Xilio Therapeutics Inc's net income was -$35.04 M.
See Xilio Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$43.77 M |
$6.34 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$1.54 M
|
$0.00
|
$0.00
|
$0.00
|
$1.50 M
|
$1.07 M
|
$240.00 K
|
| Gross Profit |
$42.23 M
|
$6.34 M
|
$0.00
|
$0.00
|
-$1.50 M
|
-$1.07 M
|
-$240.00 K
|
| Gross Profit Ratio |
0.96
|
1
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$56.04 M
|
$41.21 M
|
$52.14 M
|
$59.20 M
|
$51.19 M
|
$43.91 M
|
$14.26 M
|
| General & Administrative Expenses |
$29.71 M
|
$24.78 M
|
$27.00 M
|
$29.95 M
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$29.71 M
|
$24.78 M
|
$27.00 M
|
$29.95 M
|
$22.36 M
|
$9.59 M
|
$4.53 M
|
| Other Expenses |
-$1.54 M
|
$937.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$84.21 M
|
$66.93 M
|
$79.13 M
|
$89.15 M
|
$73.55 M
|
$53.50 M
|
$18.79 M
|
| Cost And Expenses |
$85.75 M
|
$66.93 M
|
$79.13 M
|
$89.15 M
|
$75.04 M
|
$54.56 M
|
$19.03 M
|
| Interest Income |
$3.40 M
|
$0.00
|
$0.00
|
$0.00
|
$600.00
|
$600.00
|
$0.00
|
| Interest Expense |
$0.00
|
$100.00 K
|
$0.00
|
$0.00
|
$600.00 K
|
$600.00 K
|
$0.00
|
| Depreciation & Amortization |
$1.54 M
|
$1.64 M
|
$1.90 M
|
$1.85 M
|
$1.50 M
|
$1.07 M
|
$240.00 K
|
| EBITDA |
-$33.50 M |
-$58.00 M |
-$74.50 M |
-$86.38 M |
-$73.70 M |
-$53.55 M |
-$17.07 M |
| EBITDA Ratio |
-0.77
|
-9.14
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.96
|
-9.55
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$6.95 M
|
$2.34 M
|
$2.73 M
|
$927.00 K
|
-$756.00 K
|
-$656.00 K
|
$1.72 M
|
| Income Before Tax |
-$35.04 M
|
-$58.24 M
|
-$76.40 M
|
-$88.22 M
|
-$75.80 M
|
-$55.22 M
|
-$17.31 M
|
| Income Before Tax Ratio |
-0.8
|
-9.18
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$35.04 M
|
-$58.24 M
|
-$76.40 M
|
-$88.22 M
|
-$75.80 M
|
-$55.22 M
|
-$17.31 M
|
| Net Income Ratio |
-0.8
|
-9.18
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-4.19 |
-15.26 |
-38.92 |
-45.08 |
-189.28 |
-1475.88 |
-592.06 |
| EPS Diluted |
-4.19 |
-15.26 |
-38.92 |
-45.08 |
-189.28 |
-1475.88 |
-592.06 |
| Weighted Average Shares Out |
$83.59 M
|
$3.82 M
|
$1.96 M
|
$1.96 M
|
$400.45 K
|
$37.41 K
|
$29.24 K
|
| Weighted Average Shares Out Diluted |
$83.59 M
|
$3.82 M
|
$1.96 M
|
$1.96 M
|
$400.45 K
|
$37.41 K
|
$29.24 K
|
| Link |
|
|
|
|
|
|
|
